9 results on '"Nelson J"'
Search Results
2. Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
- Author
-
Anand, Sarah, Corbet, Kelly, Gasparetto, Cristina, Long, Gwynn D., Lopez, Richard, Morris, Ashley K., Rizzieri, David A., Sullivan, Keith M., Sung, Anthony D., Sarantopoulos, Stefanie, Chao, Nelson J., Horwitz, Mitchell E., and Thomas, Samantha
- Subjects
- *
CORD blood transplantation , *MYELOSUPPRESSION , *FLUDARABINE , *TOTAL body irradiation , *CYCLOPHOSPHAMIDE , *MORTALITY prevention , *THERAPEUTICS ,DISEASES in adults - Abstract
Treatment-related mortality (TRM) remains elevated in adult patients undergoing umbilical cord blood transplantation (UCBT), including an early rise in TRM suggestive of excessive toxicity associated with the standard myeloablative total body irradiation (TBI), fludarabine, and cyclophosphamide regimen. In an attempt to reduce regimen-related toxicity, we previously studied a modified myeloablative regimen with TBI (1350 cGy) and fludarabine (160 mg/m 2 ); TRM was decreased, but neutrophil engraftment was suboptimal. Therefore, to improve engraftment while still minimizing regimen-related toxicity, we piloted a myeloablative regimen with the addition of thiotepa (10 mg/kg) to TBI and fludarabine conditioning. Thirty-one adult patients (median age, 46 years; range, 19 to 65) with hematologic malignancies (acute leukemia/myelodysplastic syndrome, 77%; lymphoid malignancy, 23%) underwent single (n = 1) or double (n = 30) UCBT from 2010 to 2015 at our institution. The cumulative incidence of neutrophil engraftment was 90% (95% confidence interval [CI], 70% to 97%) by 60 days, with a median time to engraftment of 21 days (95% CI, 19 to 26). The cumulative incidence of platelet engraftment was 77% (95% CI, 57% to 89%) by 100 days, with a median time to engraftment of 47 days (95% CI, 37 to 73). Cumulative incidences of grades II to IV and grades III to IV acute graft-versus-host disease (GVHD) at day 100 were 45% (95% CI, 27% to 62%) and 10% (95% CI, 2% to 23%), respectively. The overall incidence of chronic GVHD at 2 years was 40% (95% CI, 22% to 57%), with 17% of patients (95% CI, 6% to 33%) experiencing moderate to severe chronic GVHD by 2 years. TRM at 180 days was 13% (95% CI, 4% to 27%), at 1 year 24% (95% CI, 10% to 41%), and at 3 years 30% (95% CI, 13% to 49%). Relapse at 1 year was 13% (95% CI, 4% to 27%) and at 3 years 19% (95% CI, 6% to 38%). With a median follow-up of 35.5 months (95% CI, 12.7 to 52.2), disease-free and overall survival at 3 years were 51% (95% CI, 29% to 69%) and 57% (95% CI, 36% to 73%), respectively. This regimen represents a reasonable alternative to myeloablative conditioning with TBI, fludarabine, and cyclophosphamide and warrants further study. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
3. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
- Author
-
Sivaraj, Dharshan, Green, Michael M., Li, Zhiguo, Sung, Anthony D., Sarantopoulos, Stefanie, Kang, Yubin, Long, Gwynn D., Horwitz, Mitchell E., Lopez, Richard D., Sullivan, Keith M., Rizzieri, David A., Chao, Nelson J., and Gasparetto, Cristina
- Subjects
- *
MULTIPLE myeloma treatment , *BORTEZOMIB , *AUTOTRANSPLANTATION , *CYTOGENETICS , *FLUORESCEIN , *DRUG efficacy , *MEDICATION safety , *THERAPEUTICS - Abstract
Comprehensive recommendations for maintenance therapy after autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM) have yet to be defined. Bortezomib has been utilized as maintenance therapy after ASCT, but data attesting to the safety and efficacy of this agent compared with lenalidomide in the post-ASCT setting are limited. Therefore, we retrospectively analyzed the outcomes of 102 patients with MM who received maintenance therapy with bortezomib after ASCT at Duke University's adult bone marrow transplant clinic between 2005 and 2015. Maintenance with bortezomib was initiated between 60 and 90 days after ASCT as a single agent 1.3 mg/m 2 once every 2 weeks (n = 92) or in combination with lenalidomide (10 mg/day) (n = 10). The median age at ASCT was 64 (range, 31 to 78). Of the 99 patients with molecular data available, 42% had high-risk cytogenetics (including d17p, t(4;14), +1q, and t(14;16) by fluorescein in situ hybridization). Overall, 46% of patients experienced side effects from maintenance therapy, with 31% of all patients experiencing peripheral neuropathy. In total, 2% of patients required discontinuation of bortezomib maintenance because of adverse events. No secondary malignancies were reported from the therapy. The median progression-free survival (PFS) for patients receiving maintenance therapy with bortezomib after ASCT was 36.5 months (95% confidence interval [CI], 21.3 to not available) and median overall survival was 72.7 months (95% CI, 63.9 to not available). The PFS of patients with high-risk cytogenetics was not statistically significantly different from those with standard-risk cytogenetics, suggesting that maintenance with bortezomib may help overcome the impact of high-risk cytogenetics on early progression. These results indicate that maintenance therapy with bortezomib represents a safe, well-tolerated, and efficacious option for patients with high-risk cytogenetics, renal insufficiency, an inability to tolerate lenalidomide, or a previous history of another cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia.
- Author
-
Inamoto, Yoshihiro, Flowers, Mary E.D., Wang, Tao, Urbano-Ispizua, Alvaro, Hemmer, Michael T., Cutler, Corey S., Couriel, Daniel R., Alousi, Amin M., Antin, Joseph H., Gale, Robert Peter, Gupta, Vikas, Hamilton, Betty K., Kharfan-Dabaja, Mohamed A., Marks, David I., Ringdén, Olle T.H., Socié, Gérard, Solh, Melhem M., Akpek, Görgün, Cairo, Mitchell S., and Chao, Nelson J.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *APLASTIC anemia treatment , *TACROLIMUS , *CYCLOSPORINE , *COMBINATION drug therapy , *HEALTH outcome assessment , *MORTALITY , *THERAPEUTICS - Abstract
Combinations of cyclosporine (CSP) with methotrexate (MTX) have been widely used for immunosuppression after allogeneic transplantation for acquired aplastic anemia. We compared outcomes with tacrolimus (TAC)+MTX versus CSP+MTX after transplantation from HLA-identical siblings (SIB) or unrelated donors (URD) in a retrospective cohort of 949 patients with severe aplastic anemia. Study endpoints included hematopoietic recovery, graft failure, acute graft-versus-host disease (GVHD), chronic GVHD, and mortality. TAC+MTX was used more frequently in older patients and, in recent years, in both SIB and URD groups. In multivariate analysis, TAC+MTX was associated with a lower risk of mortality in URD recipients and with slightly earlier absolute neutrophil count recovery in SIB recipients. Other outcomes did not differ statistically between the 2 regimens. No firm conclusions were reached regarding the relative merits of TAC+MTX versus CSP+MTX after hematopoietic cell transplantation for acquired aplastic anemia. Prospective studies would be needed to determine whether the use of TAC+MTX is associated with lower risk of mortality in URD recipients with acquired aplastic anemia. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies.
- Author
-
Kanda, Junya, Long, Gwynn D., Gasparetto, Cristina, Horwitz, Mitchell E., Sullivan, Keith M., Chute, John P., Morris, Ashley, Shafique, Michael, Li, Zhiguo, Chao, Nelson J., and Rizzieri, David A.
- Subjects
- *
TRANSPLANTATION of organs, tissues, etc. , *ALEMTUZUMAB , *HEMATOLOGIC malignancies , *FLUDARABINE , *HLA histocompatibility antigens , *MELPHALAN , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Abstract: We present a comparative study on 124 patients with hematologic malignancies who had undergone reduced-intensity conditioning and then received a transplant from an HLA-matched related (MRD), an HLA-matched unrelated (MUD), or an HLA-haploidentical related (HAPLO) donor. The conditioning regimen, which consisted of fludarabine, melphalan or busulfan, and alemtuzumab was administered to patients with lymphoid (n = 62) or myeloid disease (n = 62). Mycophenolate mofetil was used as prophylaxis for graft-versus-host disease (GVHD), and 38, 58, and 33 patients received transplants from MRD, MUD, and HAPLO donors, respectively. Only 2 patients experienced primary graft failure (GF) after melphalan-based regimen, whereas 8 of the 17 patients who received a transplant from HAPLO donors experienced a primary GF after busulfan-based regimen. The cumulative incidence of grade III to IV acute GVHD in engrafted patients who had received transplants from MRD, MUD, or HAPLO donors was 3%, 11%, and 27%, respectively, and the 2-year overall survival (OS) rates were 51%, 22%, and 23%, respectively. According to multivariate analysis, transplantation from either MUD or HAPLO donors compared with MRD were adverse factors that affected the OS (P = .006 and P = .002, respectively). In conclusion, the reduced-intensity regimen that included fludarabine, busulfan, or melphalan and alemtuzumab using only mycophenolate mofetil as the GVHD prophylaxis conferred favorable outcomes in the MRD group but lower survival rates in the MUD and HAPLO groups. The busulfan-based regimen led to a high incidence of GF in the HAPLO group, suggesting the need for modification or intensification of immunosuppression. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
6. Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement
- Author
-
Martin, Paul J., Bachier, Carlos R., Klingemann, Hans-Georg, McCarthy, Philip L., Szabolcs, Paul, Uberti, Joseph P., Schuster, Michael W., Weisdorf, Daniel, Chao, Nelson J., Kebriaei, Partow, Shpall, Elizabeth J., MacMillan, Margaret L., and Soiffer, Robert J.
- Subjects
- *
CLINICAL trials , *GRAFT versus host disease , *DRUG approval , *GUIDELINES , *DRUG efficacy , *MEDICATION safety , *MEDICAL terminology , *THERAPEUTICS - Abstract
Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either prevention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a comparative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD. The panel recommended terminology for “very good partial response” (VGPR) that includes both diagnostic and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving more treatment than needed to produce or maintain complete response exceeds the harm of slight undertreatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety. The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
7. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
- Author
-
Johnston, Laura J., Brown, Janice, Shizuru, Judith A., Stockerl-Goldstein, Keith E., Stuart, Monic J., Blume, Karl G., Negrin, Robert S., and Chao, Nelson J.
- Subjects
- *
IMMUNOREGULATION , *HEART failure , *HEART diseases , *THERAPEUTICS - Abstract
Abstract: We conducted a phase II trial in 19 chronic graft-versus-host disease (cGVHD) patients with rapamycin, calcineurin inhibitors, and prednisone with the goals of controlling cGVHD, reducing prednisone use, and defining the safety of this regimen. Rapamycin was begun as second-line (n = 9) or more than second-line (n = 10) therapy. With a median follow-up of 42 months, 16 patients were evaluable for response. Nine patients discontinued rapamycin because of poor compliance/patient request (n = 2) or an adverse event (n = 7), 3 of whom were not evaluable because of withdrawal at ≤1 month or noncompliance. The adverse events included serum creatinine ≥2.4 mg/dL (n = 4), hemolytic uremic syndrome (n = 2), and relapse of malignancy (n = 1). Fifteen of 16 evaluable patients had a clinical response. Five of the 16 discontinued the drug, and 1 died of relapsed leukemia. Of the 10 patients who continued rapamycin, 2 discontinued and 1 successfully tapered all systemic immunosuppression. Three of the 10 developed progressive cGVHD with tapering immunosuppression; all responded to resumption of prior medications. Four of the 10 patients required alternate therapy for persistent or progressive cGVHD while receiving rapamycin; prednisone was discontinued (n = 2) or tapered at the time of progressive disease (n = 2). Seventeen of 19 original patients were alive. One death was due to relapsed malignancy, and 1 was due to congestive heart failure. In this report of rapamycin as cGVHD therapy, there is evidence of rapamycin’s efficacy. Given the significant toxicities described, investigation of altered administration of rapamycin and calcineurin inhibitors should be pursued in future cGVHD trials. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
8. 559 - Decreased Gram Negative Bloodstream and C. Difficile Infections with Early Ciprofloxacin/Metronidazole Prophylaxis in Myeloablative Allogeneic Hematopoietic Stem Cell Transplant.
- Author
-
Kegerreis, Kristin G., Mowery, Yvonne M., Shaw, J. Ryan, Grgic, Tatjana, Chang, Jianhong, Sito, Elizabeth, Chao, Nelson J., and Lassiter, Martha
- Subjects
- *
CLOSTRIDIOIDES difficile , *HEMATOPOIETIC stem cell transplantation , *CIPROFLOXACIN , *METRONIDAZOLE , *PREVENTIVE medicine , *THERAPEUTICS - Published
- 2017
- Full Text
- View/download PDF
9. Immune Recovery in Adult Patients after Myeloablative Dual Umbilical Cord Blood, Matched Sibling, and Matched Unrelated Donor Hematopoietic Cell Transplantation
- Author
-
Kanda, Junya, Chiou, Lun-Wei, Szabolcs, Paul, Sempowski, Gregory D., Rizzieri, David A., Long, Gwynn D., Sullivan, Keith M., Gasparetto, Cristina, Chute, John P., Morris, Ashley, McPherson, Jacalyn, Hale, Jeffrey, Livingston, John Andrew, Broadwater, Gloria, Niedzwiecki, Donna, Chao, Nelson J., and Horwitz, Mitchell E.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CORD blood , *TRANSPLANTATION immunology , *TREATMENT effectiveness , *T cell receptors , *THERAPEUTICS ,DISEASES in adults - Abstract
Immunologic reconstitution after allogeneic hematopoietic cell transplantation is a critical component of successful outcome. Umbilical cord blood (UCB) transplantation in adult recipients is associated with slow and often inadequate immune recovery. We characterized the kinetics and extent of immune recovery in 95 adult recipients after a dual UCB (n = 29) and matched sibling donor (n = 33) or matched unrelated donor (n = 33) transplantation. All patients were treated with myeloablative conditioning. There were no differences in the immune recovery profile of matched sibling donor and matched unrelated donor recipients. Significantly lower levels of CD3+, CD4+, and CD8+ T cells were observed in UCB recipients until 6 months after transplantation. Lower levels of regulatory T cells persisted until 1 year after transplantation. Thymopoiesis as measured by TCR rearrangement excision circle was comparable among all recipients by 6 months after transplantation. In a subset of patients 1 year after transplantation with similar levels of circulating T cells and TCR rearrangement excision circle, there was no difference in TCR diversity. Compared to HLA-identical matched sibling donor and matched unrelated donor adult hematopoietic cell transplantation recipients, quantitative lymphoid recovery in UCB transplantation recipients is slower in the first 3 months, but these differences disappeared by 6 to 12 months after transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.